|Articles|May 22, 2019

E-cigarette Users, Especially Women, May Be More Susceptible to Flu

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.

The side effects of smoking e-cigarettes vary among females and males and differ from the effects of smoking regular cigarettes, according to a new study presented at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas.

Meghan Rebuli, PhD, a postdoctoral research associate at the University of North Carolina at Chapel Hill and a study author, discussed the preliminary research investigating differences in immune response between non-smokers and people who use cigarettes or e-cigarettes with MD Magazine®. She said that the immune response in female e-cigarette users was “suggestive of immunosuppression” while in males it was “a mixture of immune gene upregulation and down regulation.”

“Any dysregulation of immune responses to pathogens has the potential to increase susceptibility to infection or vaccines,” added Rebuli. “Therefore, our data is suggestive that e-cigarette users, especially female e-cig users, may experience increased risk of infection.”

Rebuli especially highlighted the surprising differences between immune responses in male and female e-cigarette users.

“While we know that male and female immune systems function differently, especially in the context of respiratory virus infections, the opposing responses to virus in male and female e-cig users were striking,” said Rebuli.

The study included 47 participants, who were non-smokers, cigarette smokers, and e-cigarette users, based on self-reported use, smoking/vaping diaries, and nicotine- or tobacco-related biomarkers. Participants were inoculated with live attenuated influenza virus (LAIV) to gage the immune system response. Investigators collected epithelial lining fluid (ELF), nasal lavage fluid (NLF), nasal biopsies, and blood before and after inoculation with LAIV.

Investigators found that at baseline, cigarette smokers had increased influenza peptide cleavage activity compared to non-smokers. There was no difference between non-smokers and e-cigarette users. However, certain genes and proteins necessary for immune system functioning were suppressed in e-cigarette users, but not in cigarette smokers, compared to non-smokers.

Additionally, after LAIV was introduced, epithelial and nasal fluid samples showed that e-cigarette users had suppressed levels of interferon-gamma (IFNɣ) and IFNɣ-inducible chemokines.

While the research is early and is still in the process of being published, Rebuli said the main takeaway for providers is that e-cigarette use can disrupt normal immune response to viral infections, which is likely to detrimentally affect antiviral defenses, especially for women and girls.

Previous research Rebuli was a part of found that baseline gene expression differs between e-cigarette users and non-smokers, which this study confirmed. However, the sex-specific changes were new findings, Rebuli pointed out.

“Specifically, as compared to normal non-smokers, 104 genes were down regulated in female e-cig users, the largest response being 23-fold down regulation, again suggestive of a state of immunosuppression. In contrast in male e-cig users, 10 immune genes were upregulated,” Rebuli told MD Mag.

The abstract, “Nasal Mucosal Immune Response to Infection with Live-Attenuated Influenza Virus (LAIV) Is Altered with Exposure to E-cigarettes and Cigarettes,” was presented on May 20, 2019, at the ATS 2019 International Conference.

The article, "E-cigarettes May Leave Users Susceptible to Flu, Especially Women," originally appeared on MDMag.com.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.